Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Euronext N.V.. (4/25/22). "Press Release: BenevolentAI Lists on Euronext Amsterdam. Listed Following Business Combination with Odyssey Acquisition S.A.". Amsterdam.

Organisation Organisation BenevolentAI Ltd.
  Group BenevolentAI (Group)
Products Product Benevolent Platform®
  Product 2 investment banking
Person Person Shields, Joanna (BenevolentAI 201909 CEO)
     


> 3rd SPAC business combination on Euronext markets in 2022


Euronext today congratulates BenevolentAI, a leading, clinical-stage, AI-enabled drug discovery company, on its listing on Euronext Amsterdam (ticker code: BAI). The company has listed following the completion of its successful business combination with Odyssey Acquisition S.A., a special purpose acquisition company that listed on Euronext markets on 22 April 2022.

BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company with proven track-record of scientifically validated discoveries. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

The completion of the business combination with Odyssey, and the proceeds from the transaction, will further enable BenevolentAI to accelerate the development of its clinical pipeline and continue investing in its technology platform.

Joanna Shields, Chief Executive Officer of BenevolentAI, said: “BenevolentAI stands out in the AI-enabled drug discovery sector. Our AI platform is fully operational, scientifically validated, and supports an in-house pipeline of over 20 platform-generated drug programmes and successful commercial collaborations. Through this listing, we are well-placed to strengthen our leadership position, ensuring we can continue to accelerate investment in the development of our pipeline and technology.”


[ photo ]BenevolentAI lists on Euronext Amsterdam
Caption: Joanna Shields, CEO of BenevolentAI, and her team sounded the Gong this morning to celebrate the listing of the company on the Euronext Amsterdam. They were welcomed by Simone Huis in ‘t Veld (CEO Euronext Amsterdam) and René van Vlerken (Head of Listing Euronext Amsterdam)


About BenevolentAI

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI PlatformTM powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.


About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed equity issuers and around €6.6 trillion in market capitalisation as of end March 2022, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal.

For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).


Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.

   
Record changed: 2022-04-28

Advertisement

Picture [iito] Fighting Customers 650x100px

More documents for BenevolentAI (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top